Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium has received approval from the National Medical Products Administration [1] - The approval notice includes notification numbers 2026B01286 and 2026B01287 [1] - The drug has successfully passed the consistency evaluation of quality and efficacy for generic drugs [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) has received approval from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval and Evaluation - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory, urinary, skin, soft tissue, bone, joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and perioperative infection prevention [1] - The application for the consistency evaluation was submitted to the National Medical Products Administration in July 2024 and was accepted [1] - The company has invested approximately RMB 3.3241 million in research and development for this drug's consistency evaluation [1] Group 2: Market Impact and Strategic Advantage - Products that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, according to national policies [1] - The approval of Cefazolin Sodium is expected to expand its market share and enhance its competitive position in the market [1] - This achievement also provides valuable experience for the company in conducting consistency evaluations for future products [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd., has received approval for its injectable Cefazolin Sodium, which has passed the consistency evaluation for generic drugs, enhancing its market competitiveness and potential market share [1] Group 1: Product Approval - The injectable Cefazolin Sodium received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration [1] - The drug is indicated for treating infections caused by sensitive bacteria, including respiratory, urinary, skin, soft tissue, bone, joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for perioperative infection prevention [1] Group 2: Research and Development Investment - The company has invested approximately RMB 3.3241 million in the research and development of this drug's consistency evaluation [1] Group 3: Market Implications - Products that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, which is expected to expand the market share of the injectable Cefazolin Sodium [1] - The successful evaluation also provides valuable experience for the company in conducting future consistency evaluations for other products [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司关于注射用头孢唑林钠通过仿制药一致性评价的公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 3 月 18 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；職工董事為趙勇先生；以及獨立非執行董事為 顧朝陽先生、霍文遜先生、王忠先生及萬鈞女士。 * 僅供識別 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 证券代码： ...

证券代码：601607 证券简称：上海医药 编号：临 2026-018 上海医药集团股份有限公司 关于注射用头孢唑林钠通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药新亚药业有限公司（以下简称"上药新亚"）的注射用头孢唑林钠（以 下简称"该药品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发 的《药品补充申请批准通知书》（通知书编号：2026B01286、2026B01287）， 该药品通过仿制药质量和疗效一致性评价。 一、该药品基本情况 规格：0.5g、1.0g 药品名称：注射用头孢唑林钠 剂型：注射剂 注册分类：化学药品 三、对上市公司影响及风险提示 根据国家相关政策，通过一致性评价的品种在医保支付及医疗机构采购等领 域将获得更大的支持力度。因此上药新亚的注射用头孢唑林钠通过仿制药一致性 评价，有利于扩大该药品的市场份额，提升市场竞争力，同时为公司后续产品开 展一致性评价工作积累了宝贵的经验。 审批结论： ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang"), received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, indicating that the drug has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a key driver of economic growth [16][17]. - As of March 6, 2026, the total contract value for Chinese innovative drug outbound business development (BD) has reached USD 56.8 billion, with an upfront payment of USD 3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamental outlook for quality companies remains strong, with ongoing clinical development and internationalization efforts [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baillie Gifford [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies high-performing stocks such as Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%) for the week, while stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) faced significant declines [9].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a core engine of economic growth [16][17]. - As of March 6, 2026, the total value of business development (BD) contracts for Chinese innovative drugs has reached $56.8 billion, with an upfront payment of $3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamentals of quality companies remain solid, and the long-term growth logic for innovative drug exports is still intact [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baiyue Tianheng [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies top-performing stocks for the week, including Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%), while highlighting significant declines in stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) [9].